Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.

× No keyword cloud information.

57 in total

1. Resveratrol and Malignancies.

Authors: Rodica P Bunaciu; Andrew Yen
Journal: Curr Pharmacol Rep Date: 2015-03-10

2. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum.

Authors: Jiabo Wang; Zhijie Ma; Ming Niu; Yun Zhu; Qingsheng Liang; Yanling Zhao; Jingyuan Song; Zhaofang Bai; Yaming Zhang; Ping Zhang; Na Li; Yakun Meng; Qi Li; Lushan Qin; Guangju Teng; Junling Cao; Baosen Li; Shilin Chen; Yonggang Li; Zhengsheng Zou; Honghao Zhou; Xiaohe Xiao
Journal: Front Med Date: 2015-10-12 Impact factor: 4.592

Review 3. Therapeutic Approaches for Zika Virus Infection of the Nervous System.

Authors: Rachel P M Abrams; Jamie Solis; Avindra Nath
Journal: Neurotherapeutics Date: 2017-10 Impact factor: 7.620

4. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.

Authors: Eppie M Yiu; Geneieve Tai; Roger E Peverill; Katherine J Lee; Kevin D Croft; Trevor A Mori; Barbara Scheiber-Mojdehkar; Brigitte Sturm; Monika Praschberger; Adam P Vogel; Gary Rance; Sarah E M Stephenson; Joseph P Sarsero; Creina Stockley; Chung-Yung J Lee; Andrew Churchyard; Marguerite V Evans-Galea; Monique M Ryan; Paul J Lockhart; Louise A Corben; Martin B Delatycki
Journal: J Neurol Date: 2015-04-07 Impact factor: 4.849

Review 5. Targeting extracellular matrix remodeling in disease: Could resveratrol be a potential candidate?

Authors: Renu Agarwal; Puneet Agarwal
Journal: Exp Biol Med (Maywood) Date: 2016-10-23

6. A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.

Authors: Dan-Dan Xiong; Yue Qin; Wen-Qing Xu; Rong-Quan He; Hua-Yu Wu; Dan-Min Wei; Jing-Jing Zeng; Yi-Wu Dang; Gang Chen
Journal: Clin Drug Investig Date: 2018-10 Impact factor: 2.859

A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma.

1. Resveratrol and Malignancies.

2. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum.

Review 3. Therapeutic Approaches for Zika Virus Infection of the Nervous System.

4. An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels.

Review 5. Targeting extracellular matrix remodeling in disease: Could resveratrol be a potential candidate?

6. A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma.

Review 7. Future directions in the prevention of prostate cancer.

8. Resveratrol levels and all-cause mortality in older community-dwelling adults.

9. Inhibition of breast cancer metastasis by resveratrol-mediated inactivation of tumor-evoked regulatory B cells.

Review 10. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.